ALB and cancer: The effect of Evans blue (EB) and 4-(p-iodophenyl)butyryl (IP)-based albumin binding moieties (ABMs) on the pharmacokinetics of αvβ6-BP, a peptide targeting the cancer-associated cell surface receptor integrin αvβ6 was investigated.